Search

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2008.10.002 Byline: Minhao Zhou (a), Nathalie Johnson (b), Sam Gruner (b), G.W. Ecklund (c), Paul Meunier (c), Sally Bryn (b), Margie Glissmeyer (b), Kari Steinbock (b) Keywords: Breast-specific gamma imaging; BSGI; Preoperative breast cancer staging; Breast imaging; Magnetic resonance imaging Abstract: Breast-specific gamma imaging (BSGI) is a functional imaging modality that has comparable sensitivity but superior specificity compared with magnetic resonance imaging, yielding fewer false-positive results and thereby improving clinical management of the newly diagnosed breast cancer patient. Author Affiliation: (a) Oregon Health and Science University, Portland, OR, USA (b) Breast Health Center, Legacy Good Samaritan Hospital, 1040 N.W. 22nd Ave., Portland, OR 97210, USA (c) Body Imaging Radiology, Beaverton, OR, USA Article History: Received 25 May 2008; Revised 6 October 2008

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2005.01.039 Byline: Jennifer R. Garreau (a), Joanne Nelson (b), David Cook (c), John Vetto (a), Deb Walts (d), Louis Homer (d), Nathalie Johnson (d) Abstract: The sentinel node biopsy (SNB) technique is an important tool in the diagnosis and treatment of breast cancer and melanoma. However, surgeons in Oregon have not universally adopted its use. Author Affiliation: (a) Department of Surgery, Oregon Health & Science University, Portland, OR, USA (b) Legacy Cancer Institutes, Emanuel Hospital, Portland, OR, USA (c) St. Vincent's Medical Center, Portland, OR, USA (d) Legacy Cancer Institutes, Good Samaritan Hospital, 1130 NW 22nd, Suite 500, Portland, OR, USA

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2005.02.001 Byline: T. Miko Enomoto (a), Thomas Johnson (b), Noel Peterson (c), Louis Homer (d), Deb Walts (e), Nathalie Johnson (f) Abstract: Radiation dermatitis during therapy for breast malignancy can cause significant morbidity and delay treatment. RayGel (reduced glutathione and anthocyanins; Integrative Therapies, Portland, OR) appears to decrease this skin reaction, prompting us to undertake an objective evaluation of RayGel's effectiveness. Author Affiliation: (a) Department of Surgery, Oregon Health Sciences University, Portland, OR, USA (b) Department of Radiation Oncology, Legacy Good Samaritan Hospital, Portland, OR, USA (c) Integrative Therapies, Portland, OR, USA (d) Department of Statistics, Legacy Good Samaritan Hospital, Portland, OR, USA (e) Department of Oncology, Legacy Good Samaritan Hospital, Portland, OR, USA (f) Department of Surgery, Legacy Good Samaritan Hospital, Portland, OR, USA Article Note: (footnote) Funded by a Legacy Foundation Grant.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2005.01.032 Byline: Jennifer R. Garreau (a), Joanne Nelson (b), Regan Look (c), Deb Walts (d), Diana Mahin (d), Louis Homer (d), Nathalie Johnson (d) Abstract: The understanding of lobular carcinoma in situ (LCIS) has evolved since it was first described. LCIS once was thought to be a premalignant condition, but now it is considered a marker for increased risk for developing invasive breast cancer. We evaluated patient perception of risk, counseling, and subsequent management. Author Affiliation: (a) Department of Surgery, Oregon Health and Science University, Portland, OR, USA (b) Legacy Cancer Institutes, Emanuel Hospital, Portland, OR, USA (c) Northwest Cancer Specialists, Portland, OR, USA (d) Legacy Cancer Institutes, Good Samaritan Hospital, 1130 NW 22nd, Suite 500, Portland, OR 97210, USA

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2006.06.018 Byline: Jennifer R. Garreau (a), Tammy DeLaMelena (b), Deb Walts (b), Kasra Karamlou (b), Nathalie Johnson (b) Keywords: Hormone therapy; Side effects; Aromatase inhibitors; Tamoxifen Abstract: Hormonal therapy is a mainstay in the management of estrogen receptor-positive (ER+) breast cancer. Tamoxifen (TAM) has been the drug widely used until the recent emergence of the aromatase inhibitors (AIs). Although AIs appear to be better tolerated than tamoxifen, they do have a different safety profile and these side effects have not been well characterized in community practice. We surveyed patients with ER+ breast cancers who received adjuvant hormonal therapy to determine how these medications impacted their quality of life and whether side effects or cost influenced decisions to continue therapy. Author Affiliation: (a) OHSU Department of Surgery, Portland, OR, USA (b) Legacy Cancer Services, Good Samaritan Hospital, 1130 NW 22nd, Suite 500, Portland, OR 97210, USA Article History: Received 5 April 2006; Revised 20 June 2006

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjsurg.2006.05.013 Byline: Eugene Y. Chang, Margie Glissmeyer, Shavonne Tonnes, Tori Hudson, Nathalie Johnson Keywords: Breast cancer; Complementary therapy; Alternative therapy; Outcomes Abstract: Some breast cancer patients opt for alternative treatments in place of conventional treatments. The lack of published data on the outcome of this strategy may contribute to this trend. Author Affiliation: Legacy Cancer Services, Surgical Associates, 1130 NW 22nd St., Ste 500, Portland, OR 97210, USA Article History: Received 6 April 2006; Revised 25 May 2006